TrialNet presents results from a study with Diamyd®
Diamyd Medical AB reports that the results of a study with the Company's
antigen-based diabetes therapy Diamyd®, conducted by the research
consortium Type 1 Diabetes TrialNet did not show a statistically
significant effect of the study drug.
The American research consortium Type 1 Diabetes TrialNet presented
their results of a Phase II study with the antigen-based diabetes
therapy Diamyd® yesterday, June 27, at the American Diabetes Association
71st Scientific Sessions (ADA) in San Diego, California, USA, after the
closing of the stock market. At the same time a research article about
the study was published on the homepage of the medical journal The
Lancet entitled ”Antigen-based therapy with glutamic acid decarboxylase
(GAD) vaccine in patients with recent-onset type 1 diabetes: a
randomised double-blind trial”. The study did not reach the primary
efficacy endpoint of preserving endogenous insulin production, as
measured by meal-stimulated C-peptide, in patients treated with Diamyd®
compared to placebo. There was no statistically significant difference
in hemoglobin A1c (HbA1c) or mean daily insulin dose between the groups
receiving Diamyd® and the placebo treated group.
The Phase II study conducted by Type 1 Diabetes TrialNet is a
multicenter, randomized, double-blind study that recruited 145 patients,
3 to 45 years old, in the United States and Canada. The patients,
diagnosed with type 1 diabetes within three months of entering the
study, were divided into three equal groups of which one group received
three injections of Diamyd® (day 1, 30 and 90), one group received two
injections of Diamyd® and one injection of placebo, and one group
received three injections of placebo. All of the patients had some
endogenous insulin production left and were GAD-antibody positive at
entering the study. The patients have been followed for 12 months and
will be followed for another 12 months. Diamyd® was well tolerated, as
demonstrated by a similar number of adverse events reported in the
groups treated with Diamyd® and in the placebo group.
“The outcome in this North American study was unfortunately not better
than in our larger European Phase III study,” says Peter Zerhouni,
Acting President and CEO of Diamyd. “However, TrialNet concluded in its
presentation that Diamyd® and the active substance GAD65 may have an
effect when given earlier in the disease process to prevent type 1
diabetes, in a different treatment regimen, or in combination with other
drugs.”
On May 9, 2011, Diamyd Medical announced that a European Phase III study
with Diamyd® did not meet the primary efficacy endpoint of preserving
beta cell function at 15 months, as measured by meal-stimulated
C-peptide, although a small positive effect was seen. Furthermore,
Diamyd® was well tolerated as demonstrated by a similar number of
adverse events in the Diamyd® treated groups compared to the placebo
treated group. The follow-up period of the European Phase III study was
closed on June 1, 2011. Detailed results of the European study will be
presented later today, June 28, at the diabetes conference ADA in San
Diego.
On June 23, Diamyd announced that the Company decided to initiate
closure of the parallel US Phase III study DiaPrevent, based on a
blinded analysis of efficacy data collected to date in the study, and
the data from the European Phase III study.
An externally funded and researcher-initiated Phase II study with
Diamyd® is being conducted, aiming to prevent type 1 diabetes in
children at high risk of developing the disease. That study is not
affected by the findings in the other studies with Diamyd®.
For more information, please contact:
Peter Zerhouni, Acting President and CEO Diamyd Medical AB (publ.)
Phone: 46 8 661 0026
For press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
press@diamyd.com (press@diamyd.com)
Phone: 46 8 661 0026
